title: Potential antianxiety activity of Fumaria indica: A preclinical study.
abstract: BACKGROUND
  In the view of diverse CNS modulating properties of Fumaria indica, present study was planned to evaluate its putative anxiolytic activity in behavioural models of rats, followed by elucidation of mechanism of observed activity through biochemical estimations.
  
  
  METHODS
  Effects of seven daily 100, 200 and 400 mg/kg oral doses of a Fumaria indica extract (FI) was compared with those of an acute oral dose (5 mg/kg) of lorazepam in a battery of rat models consisting of open-field, elevated plus and zero maze, social interaction, and novelty induced feeding tests.
  
  
  RESULTS
  Dose dependant antianxiety effects of FI observed in all tests were qualitatively similar to those of the reference anxiolytic drug. Although FI treatments did not alter the concentrations of noradrenaline and serotonin in hippocampus and hypothalamus, concentrations of both these monoamines were dose dependently elevated in prefrontal cortex of FI treated animals. Flunitrazepam binding in brain frontal cortex was also elevated by the extract. Moreover, higher levels of brain expressions of the cytokines TNF-α, IL-1β, and IL-10 observed in animals with prior experience on elevated plus maze were almost completely reversed by the lowest dose of FI tested in the behavioral models.
  
  
  CONCLUSIONS
  Taken together, these observations strongly suggest that FI is a functionally novel type of antianxiety agent, and that inhibition of cytokine expressions in the brain could be involved in its mode of action.
authors: Neuropharmacology Research Laboratory, Department of Pharmaceutical Engineering, Indian Institute of Technology (Banaras Hindu University), Varanasi, India.
authors: Gireesh K
authors: GK
authors: Singh
authors: Sudhir K
authors: SK
authors: Chauhan
authors: Geeta
authors: G
authors: Rai
authors: Shyam S
authors: SS
authors: Chatterjee
authors: Vikas
authors: V
authors: Kumar
keywords: Antianxiety activity; Fumaria indica; behavioral psychopharmacology; cytokines; flunitrazepam binding; monoamines
references: Neurotoxicology. 1982 Nov;3(3):13-9
references: 6298678
references: Phytomedicine. 2008 Jun;15(6-7):470-7
references: 18164606
references: Curr Top Behav Neurosci. 2010;2:121-60
references: 21309109
references: Br J Pharmacol. 2011 Oct;164(4):1129-61
references: 21545412
references: Indian J Exp Biol. 2000 Jan;38(1):36-41
references: 11233082
references: Curr Opin Investig Drugs. 2001 Aug;2(8):1108-11
references: 11892922
references: J Ethnopharmacol. 2011 Apr 12;134(3):992-5
references: 21291982
references: Psychopharmacology (Berl). 2011 Feb;213(2-3):171-82
references: 20386882
references: Neuropharmacology. 2006 Jun;50(8):934-40
references: 16530230
references: Anal Biochem. 1969 Aug;30(2):161-79
references: 5809660
references: Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):343-8
references: 17805436
references: Br J Dermatol. 2001 Jun;144(6):1114-20
references: 11422029
references: J Pharmacol Pharmacother. 2011 Jul;2(3):191-2
references: 21897716
references: J Psychiatr Res. 2008 Dec;43(2):89-97
references: 18394646
references: Indian J Exp Biol. 2008 Sep;46(9):633-8
references: 18949892
references: Mt Sinai J Med. 2008 May-Jun;75(3):248-62
references: 18704983
references: Clin Immunol. 2012 Jan;142(1):44-8
references: 21414846
references: Curr Neuropharmacol. 2009 Mar;7(1):60-4
references: 19721818
references: Cardiovasc Psychiatry Neurol. 2009;2009:187894
references: 19936104
references: Anc Sci Life. 1994 Jan;13(3-4):271-3
references: 22556660
references: Neurosci Res. 2010 Dec;68(4):261-75
references: 20804792
references: Arch Intern Med. 2006 Oct 23;166(19):2109-16
references: 17060541
references: Ann Intern Med. 2007 Mar 6;146(5):317-25
references: 17339617
references: J Ethnopharmacol. 1998 Apr;60(3):207-13
references: 9613834
references: Pharmacol Biochem Behav. 2011 Jan;97(3):406-15
references: 20869983